Transforming growth factor-b is a central mediator of the malignant phenotype of glioblastoma, the most common and malignant form of intrinsic brain tumours. Transforming growth factor-b promotes invasiveness and angiogenesis, maintains cancer cell stemness and induces profound immunosuppression in the host. Integrins regulate cellular adhesion and transmit signals important for cell survival, proliferation, differentiation and motility, and may be involved in the activation of transforming growth factor-b. We report that avb3, avb5 and avb8 integrins are broadly expressed not only in glioblastoma blood vessels but also in tumour cells. Exposure to av, b3 or b5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or pharmacological integrin inhibition using the cyclic RGD peptide EMD 121974 (cilengitide) results in reduced phosphorylation of Smad2 in most glioma cell lines, including glioma-initiating cell lines and reduced transforming growth factor-b-mediated reporter gene activity, coinciding with reduced transforming growth factor-b protein levels in the supernatant. Time course experiments indicated that the loss of transforming growth factor-b bioactivity due to integrin inhibition likely results from two distinct mechanisms: an early effect on activation of preformed inactive protein, and second, major effect on transforming growth factor-b gene transcription as confirmed by decreased activity of the transforming growth factor-b gene promoter and decreased transforming growth factor-b 1 and transforming growth factor-b 2 messenger RNA expression levels. In vivo, EMD 121974 (cilengitide), which is currently in late clinical development as an antiangiogenic agent in newly diagnosed glioblastoma, was a weak antagonist of pSmad2 phosphorylation. These results validate integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to block transforming growth factor-b-controlled features of malignancy including invasiveness, stemness and immunosuppression in human glioblastoma.
Introduction
Human glioblastoma is a highly lethal brain tumour that kills affected patients by local destructive growth. Surgery, radiotherapy and alkylating agent chemotherapy represent the current standard of care, which results in a median overall survival of 51 year on a population level (Preusser et al., 2011) . Transforming growth factor (TGF)-b is a master molecule controlling migration, invasiveness and angiogenesis in glioblastoma and induces profound immunosuppression (Wick et al., 2006) . More recently, TGF-b has also been attributed to an important role in maintaining the population of cells within glioblastomas exhibiting stem cell-like properties, often (and also herein) referred to as glioma-initiating cells (Penuelas et al., 2009; Anido et al., 2010) . Rodent glioma models have confirmed TGF-b as an attractive target for experimental approaches using gene silencing or small-molecule TGF-b receptor antagonists (Friese et al., 2004; Uhl et al., 2004; Zhang et al., 2011) . Clinical data confirm that TGF-b/Smad pathway activity confers a poor prognosis to glioma patients (Bruna et al., 2007) , and TGF-b antagonism is currently explored as a therapeutic strategy in recurrent glioblastoma (Bogdahn et al., 2011; Azaro et al., 2012) . However, although the important role of TGF-b in glioblastoma and other cancers is widely accepted, its therapeutic targeting has remained challenging.
TGF-b is secreted in a latent complex with its processed propeptide, latency-associated peptide (Annes et al., 2003) in the small latent complex. Latent TGF-b-binding proteins covalently bind the small latent complex to form the large latent complex (Miyazono et al., 1991) . Activation of TGF-b necessitates dissociation from the small latent complex, which involves proteolytic cascades or cell traction forces (Wipff and Hinz, 2008) . Integrins constitute a large family of cell surface transmembrane molecules that are composed of an -and a b-subunit. Eighteen -subunits and b-subunits form 24 different heterodimeric integrin molecules, which mediate various complex processes including adhesion, migration and angiogenesis in a cell type-and context-dependent manner (Desgrosellier and Cheresh, 2010) . Importantly, integrins may also play an important, but complex, role in activating TGF-b (Sheppard, 2005; Wipff and Hinz, 2008) . Diverse integrins, including all v integrins, interact with the latency-associated peptide/TGF-b 1 portion of the large latent complex via a L-arginine, glycine, and L-aspartic acid (RGD) motif (Ludbrook et al., 2003; Sheppard, 2005) and vb6 and vb3 may support TGF-b 1 activation (Munger et al., 1999; Mu et al., 2002) . However, TGFb 2 /latency-associated peptide does not contain an RGD sequence, and whether TGF-b 2 activation depends on other integrin-dependent mechanisms remains unclear (Sheppard, 2005) . Additionally, TGF-b 1 transcription and secretion are stimulated through integrin activation via an Arg-Gly-Asp-Ser (RGDS) peptide in human mesangial cells (Ortega-Velazquez et al., 2003) . Taken together, these observations prompted us to explore the possibility of down regulating the TGF-b pathway in glioblastoma by interfering with the expression or function of specific integrins expressed in these tumours.
Materials and methods

Cells and reagents
The human malignant glioma cell lines U87MG and T98G were from the American Type Culture Collection. LN-18, LNT-229 and LN-308 cells were kindly provided by N. de Tribolet (Lausanne, Switzerland). The generation, characterization and culturing of glioma-initiating cell lines GS-2, GS-3, GS-5 and GS-9 have been described previously (Gunther et al., 2008) . These cells were maintained as sphere cultures. Transfected mink lung epithelial cells, a kind gift from D.B. Rifkin (New York, NY), were maintained in Dulbecco's modified Eagle's medium containing 10% foetal calf serum (Biochrom) supplemented with G418 (800 mg/ml, Biochrom). Accutase TM was obtained from PAA. Recombinant human TGF-b 1 was purchased from R&D Systems. Except for immunohistochemistry, the following antibodies were used for all experiments: rabbit polyclonal antibody to TGF-b 2 and goat polyclonal antibody to actin were obtained from Santa Cruz Biotechnology. TGF-b 1 , phospho-Smad2 (Ser465/467) (clone 138D4) and Smad2 (clone 86F7) antibodies were purchased from Cell Signaling Technology. Mouse anti-Smad2/3 antibody was from BD Biosciences. Anti-v antibody (clone 17E6) was obtained from Merck. The antibodies to vb3 (clone LM609, MAB1976), vb5 (clone P1F6, MAB1961) and to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were from Chemicon. Mouse serum-free hybridoma supernatant to integrin b8 (Ab14e5), a generous gift from S.L. Nishimura (San Francisco, CA), was used at a dilution of 1:100 for flow cytometry. Murine isotype mouse IgG 1 from murine myeloma was purchased from Sigma-Aldrich. The TGF-b receptor I kinase inhibitor SD-208 was kindly provided by Scios Inc. Cilengitide was provided by Merck (Darmstadt, Germany). For transient transfections, 3 Â 10 5 glioma cells were seeded in a six-well plate and transfected with 100 nM of small interfering RNA pools against a specific integrin or irrelevant scrambled control. For all integrins, two different small interfering RNA pools were purchased (Dharmacon/Thermo), using Metafectene Õ Pro (Biontex).
Real-time polymerase chain reaction
Total RNA was prepared using the RNeasy Õ system including DNase treatment (Qiagen) and transcribed according to standard protocols. Complementary DNA was prepared using SuperScript Õ RNase H À Reverse Transcriptase (Invitrogen) and random nonamers (Cell Signaling). For real-time PCR, gene expression was measured in an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with SYBR Green Master Mix (Eurogentec) and primers (SigmaAldrich) at optimized concentrations. GAPDH primers have been previously described (Carraro et al., 2005) . The other sequences were as follows:
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Immunoblot analysis
For the detection of proteins from cell lysates, cells were lysed in radioimmunoprecipitation assay buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 1 Â complete inhibitor mix (Roche Diagnostics) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich). Serum-free conditioned media were concentrated with the centriplus centrifugal filter device YM-3 (3000 Da cut-off; Millipore). Protein levels were analysed by immunoblot using 20 mg of protein per lane mixed with Laemmli buffer containing b-mercaptoethanol, unless otherwise indicated, with the respective antibodies used at the concentrations recommended by the manufacturer. Equal protein loading was ascertained by Ponceau S staining. Visualization of protein bands was accomplished using horseradish peroxidise-coupled secondary antibodies (Sigma-Aldrich) and enhanced chemiluminescence (Perbio).
Flow cytometry
Glioma cells were detached using Accutase TM (PAA), resuspended in buffer for flow cytometry (PBS, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.5% bovine serum albumin) and incubated for 30 min on ice using the respective antibodies or isotype-matched control antibody. This was followed by an R-phycoerythrin-conjugated goat anti-mouse IgG antibody (1:40) labelling step. Fluorescence was detected in a CyanADP flow cytometer (DakoCytomation). Specific fluorescence indices were calculated by dividing the mean fluorescence obtained with the specific antibody by the mean fluorescence obtained with the control antibody.
TGF-b 1/2 enzyme-linked immunosorbent assay
The cells (2 Â 10 5 /well) were seeded in a six-well plate and exposed to the control peptide RAD or cilengitide as indicated. Supernatants were harvested after 48 h. To activate latent TGF-b 1/2 to the bioactive form, hydrochloric acid was added, followed by incubation at room temperature for 15 min. Acidified samples were neutralized with sodium hydroxide. Subsequently, the samples were serially diluted with PBS. TGF-b 1 and -b 2 concentrations were measured by Enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's protocol (R&D Systems).
Immunohistochemistry
Gliomas of different World Health Organization (WHO) grades of malignancy were analysed on a tissue microarray. The tissue microarray was constructed as previously described (Kononen et al., 1998) and contained 14 grade II, 27 grade III and 26 grade IV primary gliomas. Two 0.6 mm cores were punched from each of the 67 tumour paraffin blocks. Tissue microarray sections were incubated according to Ventana automat protocols (Ventana Medical System) using the following rabbit monoclonal primary antibodies: anti-integrin pan-v (clone EM01309, 1:10 000), anti-integrin vb3 (clone EM22703, 1:200), anti-integrin vb5 (clone EM09902, 1:1000), antiintegrin vb6 (clone EM05201, 1:2000) and anti-integrin vb8 (clone EM13309, 1:750) as described (Goodman et al., 2012) . The immunostaining was performed using anti-rabbit secondary antibodies with iView TM or ultraView TM Amp kits (Ventana). The intensity of integrin staining for pan-v, vb3, vb5, vb6 and vb8 was scored 0 (negative), + 1 (weak), + 2 (moderate) and + 3 (strong) in tumour cells as well as in endothelial cells. Contingency table analysis and Pearson's chi-square tests were used for the analysis of the associations between integrin expression patterns and glioma grade.
Immunofluorescence microscopy
Immunofluorescence studies were carried out on cytospins (5 Â 10 5 cells/slide). Samples were dried for 30 min and fixed in a 4% buffered formalin solution for 10 min at room temperature. Subsequently, antibody to pSmad2 (Cell Signaling) was applied (overnight at 4 C).
Binding specificity was controlled by IgG isotype control (Jackson Immunoresearch). For visualization, Cy3-conjugated AffiniPure donkey anti-rabbit IgG (Jackson Immunoresearch) was applied. All sections were mounted in Vectashield Mounting Media with 4',6-diamidino-2-phenylindole (DAPI).
TGF-b activity assay
Transfected mink lung epithelial cells, stably transfected with a luciferase gene driven by TGF-b-responsive plasminogen activator inhibitor-1 promoter sequences (Abe et al., 1994) , were seeded in 96-well plates and allowed to adhere overnight. Serum-free medium supplemented with recombinant human TGF-b for the generation of a standard curve, naïve glioma-conditioned medium for active TGF-b estimation or heat-treated (80 C, 5 min) conditioned medium for total TGF-b estimation were added to the transfected mink lung epithelial cells, which were harvested 18 h later. Luciferase activity was measured using the luciferase assay system (Promega).
Reporter assay
Intracellular TGF-b signalling was assessed by reporter assays using the pGL3-SBE4-Luc (Zawel et al., 1998) reporter plasmid kindly provided by B. Vogelstein (Baltimore, MD). The pGL2-3TP-Luc construct contains a synthetic promoter composed of a TGF-b-responsive plasminogen activator inhibitor-1 promoter fragment inserted downstream of three phorbol ester-responsive elements and was kindly provided by J. Massague (New York, NY). The pGL3-TGF-b 1 -453-luc plasmid includes the wild-type TGF-b 1 promoter fragment À 453/ + 1 fused to the luciferase gene (Weigert et al., 2002) . The pGL3À 1065/ + 11 plasmid harbours nucleotides À1065 to + 11 of the human TGF-b 1 promoter (Weigert et al., 2004) . Both constructs were generous gifts from C. Weigert (Tuebingen, Germany). Three reporter plasmids with different fragments of the TGF-b 2 -promoter were kindly provided by C. Knabbe (Stuttgart, Germany). The pGL3-TGF-b 2 -promoter constructs contain the following parts of the promoter: ( À1729/ + 64 wild-type), ( À778/ + 64 wild-type) and ( À531/ + 64 wild-type) (Beisner et al., 2006) . Dual luciferase/renilla assays were performed with co-transfection of 150 ng of the respective reporter construct and 20 ng of pRL-CMV. Luciferase activity was normalized to constitutive renilla activity (pRL-CMV).
Animal studies
Athymic CD1 nude mice were purchased from Charles River Laboratories. Mice of 6-12 weeks of age were used in all experiments. The experiments were approved by the local authorities. Before all intracranial procedures, mice were anaesthetized by an intraperitoneal 3-component injection comprising fentanyl, midazolam and medetomidin. For intracranial implantation, the mice were placed in a stereotactic fixation device (Stoelting) and a burr hole was drilled in the skull 2-mm lateral and 1-mm posterior to the bregma. The needle of a Hamilton syringe was introduced to a depth of 3 mm. LN-308 glioma cells (10 5 ) in a volume of 2 ml PBS were injected into the right striatum. Six weeks after tumour inoculation, cilengitide (90 mg/kg) or PBS were injected on five consecutive days. Three hours after the last injection, all mice were sacrificed and brain cryosections were immediately prepared for haematoxylin and eosin staining or for further analyses. pSmad2 expression was assessed by immunofluorescence microscopy as described above. All pictures were taken with a Â 63 oil immersion objective (1.4 numerical aperture; Leica Microsystems). A CLSM Leica SP5 microscope (Leica Microsystems) attached to a diode and a helium neon laser were used to provide excitation at 405 nm and 561 nm wavelengths. The emitted fluorescence light was detected via two adjustable photomultiplier detectors. Three single images from different brain sections from one animal were recorded and included in the quantification. The surface detection function from Bitplane Imaris (Bitplane) was used to identify all DAPI-positive areas as nucleus per picture and to exclude extranuclear signals. The total fluorescence intensity of Cy3 in each nucleus was determined and normalized to the nucleus size (fluorescent intensity/mm 2 nucleus area) to avoid false signals because of different nucleus sizes. The total fluorescence intensity of three pictures of three animals per group was averaged.
Statistics
Data are expressed as mean and standard deviation. The experiments shown were repeated three times with similar results. Analysis of significance was performed using the two-tailed Student's t-test (Excel, Microsoft) (*P 5 0.05, **P 5 0.01).
Results
Integrin expression in human gliomas in vivo and in glioma-initiating cell lines in vitro
Integrins vb3 and vb5 are expressed in tumour vasculature and integrins vb6 and vb8 have been attributed to a role in TGF-b activation (Munger et al., 1999; Mu et al., 2002; Cambier et al., 2005; Alghisi and Ruegg, 2006) . This prompted us to determine the expression of these integrins by immunohistochemistry on tissue microarray of gliomas of different WHO grades of malignancy. In glioblastomas, no staining for vb6 was found, whereas a rather homogeneous expression pattern was observed for the other v integrins (Fig. 1A) . The integrin expression in endothelial cells versus tumour cells proper was separately analysed in gliomas of different WHO grades. No vb6 expression was detected in any glioma either in tumour or endothelial cells. In endothelial cells, the antibodies to pan-v revealed a homogenous expression pattern in all gliomas. In contrast, the expression of integrin vb3 was higher in glioblastoma tissue than in grade II and III tumours, whereas vb5 levels were higher in grade II tumours than in grade III and IV gliomas. No staining was observed for vb8 in endothelial cells of any glioma (Fig. 1B) . Tumour cells within glioblastoma tissue displayed higher v, vb5 and vb8 expression levels than in WHO grade II and III tumours. The antibody to integrin vb3 revealed faint patterns of expression, but also with the highest levels in grade IV gliomas (Fig. 1C) . The expression of integrins vb3 and vb5 in long-term glioma cell lines has previously been characterized in our laboratory (Maurer et al., 2009 ). Here we confirmed expression of the relevant integrins in LN-308 cells ( Fig. 2A) and further demonstrated the presence of these integrins on the surface of gliomainitiating cell lines (Fig. 2B) .
Integrin inhibition interferes with Smad2 phosphorylation in human glioblastoma cells
If integrin inhibition impaired TGF-b activation, a reduced phosphorylation of Smad2, a central effector of TGF-b signalling, would be predicted to occur. Accordingly, LN-308 glioma cells treated with antibodies specifically blocking different v integrins exhibited reduced Smad2 phosphorylation after 48 h (Fig. 3A) . Similarly, we used small interfering RNA oligonucleotides to specifically silence the expression of single integrins in LN-308 glioma cells. Compared with control transfectants, the cell surface expression of all integrins was strongly reduced (Supplementary Fig. 1A ).
Integrin gene silencing was confirmed to be specific, e.g. b5 gene silencing did not affect expression of the other integrins ( Supplementary Fig. 1B ). Reduced pSmad2 levels were observed relative to cells treated with scrambled control small interfering RNA oligonucleotides (Fig. 3A) . Further, Smad2 phosphorylation in LN-308 cells declined as soon as 4 h after exposure to cilengitide, a cyclic RGD pentapeptide with high affinity for integrins vb3 and vb5 (Mas-Moruno et al., 2010) (Fig. 3A) . The glioma cell lines LN-18, U87MG, T98G and to a moderate degree LNT-229 too showed reduced pSmad2 levels when treated with cilengitide (Fig. 3A) . This reduction in pSmad2 levels was paralleled with an increase in total Smad2/3 levels, most prominently in LNT-229 cells, and probably reflects a negative feedback loop. The loss of pSmad2 induced by cilengitide was already apparent at 1 mM, near the IC 50 for cilengitide-mediated inhibition of vb3/vb5-dependent glioma cell attachment (Maurer et al., 2009 ). The addition of exogenous TGF-b 1 at 52 ng/ml restored Smad 2 phosphorylation in LN-308 cells (Supplementary Fig. 2A ), but did not restore attachment. Still, we considered the possibility that loss of pSmad2 resulted from detachment alone, and observed that poly-HEMA-mediated detachment promoted a loss of pSmad2 and an increase of total Smad2/3 ( Supplementary Fig.  2B ). Therefore, to assess whether the loss of pSmad2 is a specific effect of cilengitide or rather a result of detachment, we examined the attached and detached LN-308 cell fractions for pSmad2 in response to cilengitide separately. Interestingly, Smad2 dephosphorylation was even more prominent in those LN-308 cells still attached to the cell culture flasks than in the detached fraction floating in the media ( Supplementary Fig. 2B ). Thus interference with Smad2 phosphorylation is likely to be a specific effect of cilengitide on glioma cells and not simply a result of cell detachment.
To confirm the assumption that interference with integrin signalling results in a suppression of the Smad2 pathway, we transiently transfected LN-308 or LNT-229 cells with a reporter construct containing four copies of the Smad-binding site (SBE4-Luc) or the artificial TGF-b reporter plasmid 3TP-Luc. These constructs report TGF-b signalling, which was significantly reduced when the cells were exposed to integrin-blocking antibodies, specific small interfering RNA oligonucleotides or cilengitide, but not with their corresponding controls (Fig. 3B) .
Inhibition of integrin activity decreases TGF-b protein release by glioma cells
We next sought to clarify the mechanisms underlying reduced pSmad2 levels and decreased TGF-b-dependent reporter activity and assessed the effects of integrin inhibition on total TGF-b 1 and TGF-b 2 levels in the cell culture media by ELISA. Exposure of LN-308 glioma cells to integrin-blocking antibodies resulted in decreased TGF-b 1 and TGF-b 2 protein levels in the cell culture supernatant after 48 h. The strongest reduction in TGF-b protein levels was observed in cells that had been exposed to the pan integrin v antibody 17E6, closely followed by vb3 and vb5 inhibition (Fig. 4A) . When using RNA interference to specifically silence single integrins, a strong reduction of TGF-b 1 and TGF-b 2 protein was also observed. Cells with a knock-down of integrin v displayed the most prominent decrease in TGF-b expression. However, the expression levels of TGF-b were reduced by the knock-down of each integrin chain investigated (Fig. 4B) . Additional experiments with a second set of small interfering RNA oligonucleotides resulted in a specific knock-down of integrins ( Supplementary Fig. 3A ) and a reduction of TGF-b levels ( Supplementary Fig. 3B ). Finally, exposure of glioma cells to cilengitide also resulted in decreased TGF-b 1 (Fig. 4C) , and more prominently TGF-b 2 levels (Fig. 4C) in all glioma cell lines tested. Prominent reductions were noticed in LN-18, T98G and LN-308 Integrin inhibition suppresses TGF-b signalling in glioblastoma cells below 50% (Fig. 4C) . Similarly, most glioma-initiating cell lines responded to cilengitide with decreased TGF-b levels in the cell culture medium (Fig. 4C) .
If cilengitide was affecting the TGF-b pathway mainly by acting on the activation of latent TGF-b, then there should be a difference between the ratios of latent as opposed to active TGF-b between control-treated and cilengitide-treated cells. Interestingly, at 1-mM exposure for 24 h, cilengitide had significant effect on active, but not total, levels of TGF-b, whereas both active and total TGF-b were reduced at 10 mM (Fig. 4D) , suggesting a dual mode of action of integrin inhibition and TGF-b bioactivity. (top), or transiently transfected with small interfering RNA oligonucleotides specific for one integrin or a control small interfering RNA (middle), were assessed for pSmad2 and total Smad2/3 levels by immunoblot, using GAPDH as a loading control. In the bottom panel, LN-308, LN-18, U87MG, T98G or LNT-229 cells were exposed to control peptide ( À ) or cilengitide (10 mM) as indicated and assessed for pSmad2 and total Smad2/3 levels. (B) LN-308 or LNT-229 cells were exposed to blocking antibodies (top) or small interfering RNA oligonucleotides (middle) as in (A). In the bottom panel, LN-308 or LNT-229 cells were exposed to the control peptide RAD (black bars), 2.5 mM (light grey) or 10 mM (dark grey) cilengitide for 24 h. Intracellular TGF-b signalling was assessed by reporter assays using the pGL3-SBE4-Luc and pGl2-3TP-Luc constructs (*P 5 0.05 and **P 5 0.01 compared with isotype control and scrambled small interfering RNA or RAD, respectively). levels as determined by real-time PCR (Fig. 5A) . Integrin gene silencing using RNA interference also resulted in decreased TGFb 1 and TGF-b 2 messenger RNA levels with strongest effects observed after silencing of integrin v. Finally, we investigated the effects of cilengitide on TGF-b transcripts. Time course analyses of messenger RNA levels in LN-308 cells revealed a reduction in TGF-b 1 and TGF-b 2 messenger RNA (by 450%) within 24 h of exposure to cilengitide, suggesting a transcriptional repression of the TGF-b genes by cilengitide (Fig. 5A ). Yet, only minor changes at 4 and 12 h were observed, especially for TGF-b 1 , a time point where pSmad levels were already reduced (Fig. 3A) .
To confirm the findings obtained by real-time PCR, we examined the effects of all three approaches of integrin inhibition on the TGF-b 1 and TGF-b 2 promoter. Both reporter plasmid constructs are sensitive to changes in the transcription of the respective TGF-b gene. Consistent with the messenger RNA data, targeting integrins with blocking antibodies or small interfering RNA oligonucleotides also induced a reduction of relative luciferase activity in LN-308 and LNT-229 glioma cells (Fig. 5B) . A reduction of luciferase activity was also observed when the cells were exposed to cilengitide. Here we examined two constructs of different lengths of the TGF-b 1 promoter and three constructs of different lengths of the TGF-b 2 upstream promoter. For both the TGF-b 1 and -b 2 promoters, a similar reduction in expression levels was noticed independently of the size of the promotor fragment (531-1729 bp upstream).
Cilengitide induces Smad2 dephosphorylation in vivo
Compared with blocking antibodies and small interfering RNA oligonucleotides, cilengitide is the clinically most advanced approach to target integrins in glioblastoma. Therefore, we aimed to determine the effect of cilengitide on TGF-b signalling in vivo. As a prerequisite, we examined Smad2 phosphorylation in LN-308 glioma cells by immunofluorescence microscopy in vitro and observed reduced pSmad2 levels after exposure to cilengitide, using SD-208 as a positive control (Fig. 6A) . For in vivo analyses, glioma-bearing nude mice were treated with cilengitide or PBS for five consecutive days. Histopathological analyses demonstrated the presence of tumours in all mice. We also confirmed the expression of the target integrins in vivo, which was unchanged after 5 days of cilengitide treatment (Fig. 6B) . Immunofluorescent stainings displayed heterogeneous effects of cilengitide on Smad2 phosphorylation in the cilengitide-treated mice. In some animals, there was a distinct reduction of pSmad2 levels, whereas other mice appeared not to respond to cilengitide (Fig. 6C) . A comprehensive quantification of pSmad2 staining revealed a non-significant trend towards reduced Smad2 phosphorylation in the cohort of cilengitide-treated mice (Fig. 6D) .
Discussion
Glioblastoma remains a major challenge in the field of clinical neuro-oncology. The addition of alkylating chemotherapy to radiotherapy has increased the median survival of patients to $15 months in clinical trials (Stupp et al., 2005) . Hope for further improvement centres on several novel therapeutic agents that are currently being investigated within clinical trials, notably antiangiogenic agents. The switch of a tumour to an angiogenic phenotype is believed to be one essential step in the multistage process towards malignancy (Hanahan and Folkman, 1996) . The tumour vasculature is therefore now seen as a promising therapeutic target in oncology. Antiangiogenic agents in advanced clinical development for glioblastoma include the vascular endothelial growth factor antibody bevazicumab (Vredenburgh et al., 2007) , the vascular endothelial growth factor receptor antagonist cediranib (Batchelor et al., 2010) and the vb3 and vb5 integrin antagonist, cilengitide (Reardon et al., 2008; Stupp et al., 2010) . Despite advanced clinical evaluation, the mechanisms that mediate clinically beneficial effects of cilengitide in particular, and integrin inhibition in general, remain unknown. Both endothelial and tumour cells might be target cells for such approaches because both express integrins in glioblastoma, albeit in a heterogeneous manner: vb3 was expressed typically at high levels in endothelial cells, which were vb8-negative, and tumour cells within glioblastomas expressed all three target integrins, but preferentially vb5 and vb8 (Fig. 1) .
TGF-b has been considered as a promising therapeutic target because of its multiple effects contributing to some of the hallmarks of malignant gliomas such as invasiveness or poor immunogenicity (Wick et al., 2006) . Its regulation by integrins has not been studied in glioblastoma. Because a biologically relevant downregulation of TGF-b should reduce Smad2 phosphorylation, we first explored this pathway in several glioma cell lines. Targeting single integrin complexes with blocking antibodies or small interfering RNA-mediated integrin gene silencing resulted in a downregulation of Smad2 phosphorylation in LN-308 glioma cells (Fig. 3A) . Owing to the lack of a commercially available antibody with blocking properties against vb8, we could target this integrin only by RNA interference. When LN-308 cells were exposed to cilengitide, a downregulation of Smad2 phosphorylation was observed as soon as 4 h after addition of the compound. This effect peaked at 48 h, and was also seen in other glioma cell lines. As previously reported, some glioma cell lines detach in the presence of cilengitide (Maurer et al., 2009) , but the effects of cilengitide on Smad2 phosphorylation were independent of detachment. Rather as we show here, they reflect a specific integrin blockade by cilengitide. Smad2 dephosphorylation was more pronounced in cells that remained attached in response to cilengitide compared with detached cells, confirming that Smad2 dephosphorylation is not mediated solely by cell detachment (Supplementary Fig. 2B ). Exogenous recombinant TGF-b counteracted the effect of cilengitide on Smad2 phosphorylation, suggesting that cilengitide does not directly block TGF-b receptor-mediated signalling, indeed, as yet few off-target effects have been identified for cilengitide (Supplementary Fig. 2A ). Consistent with these findings, the activity of two reporter constructs reflecting Smad2/TGF-b signalling was significantly reduced when the cells were exposed to integrin-blocking antibodies, specific small interfering RNA oligonucleotides, cilengitide, but not with the appropriate controls (Fig. 3B) . Next we asked whether the effects of integrin inhibition on pSmad2 levels and messenger RNA expression levels were determined by real-time PCR after 48 h and normalized to isotype-treated cells (top). LN-308 glioma cells were transiently transfected with small interfering RNA oligonucleotides specific for one integrin or a control small interfering RNA and TGF-b 1 and -b 2 messenger RNA levels were determined (middle). TGF-b 1 or -b 2 messenger RNA expression were assessed by real-time PCR after exposure to 10 mM cilengitide (Cil) at the indicated time points and compared with cells that had been exposed to control peptide (bottom). (B) Glioma cells were transfected with constructs of different lengths of the TGF-b 1 or TGF-b 2 promoter and treated as in (A) (*P 5 0.05 and **P 5 0.01 compared with isotype control and scrambled small interfering RNA or the control peptide RAD, respectively).
TGF-b-dependent reporter activity resulted from a loss of TGF-b protein in the supernatant. Indeed, integrin inhibition with all three approaches reduced TGF-b protein levels in the glioma cell culture supernatant (Fig. 4A-C) .
Previous findings suggested a link between integrin signalling and post-transcriptional processing of TGF-b (Munger et al., 1999; Mu et al., 2002) . However, glioma cell supernatants from cilengitide-treated cells showed reduced TGF-b bioavailability, both active and total TGF-b, and not only of active TGF-b, suggesting that interference with activation is not the sole activity of cilengitide. However, Fig. 4D indicates that specifically lower concentrations may exert an effect on TGF-b activity in the absence of effects on total TGF-b. Figure 6 Effects of cilengitide on Smad2 phosphorylation in LN-308 gliomas in vivo. (A) LN-308 glioma cells were exposed to RAD or cilengitide (10 mM), TGF-b 2 (10 ng/ml) or SD-208 (1 mM) and assessed for pSmad2 expression after 48 h by immunofluorescence microscopy (original magnification Â40). (B) LN-308 cells were inoculated intracerebrally in athymic CD1 nude mice. The animals were treated intraperitoneally with cilengitide (90 mg/g body weight) or PBS for 5 days starting 3 weeks after tumour cell inoculation. Subsequently, the animals' brains were removed, shock-frozen and integrin expression was assessed by immunohistochemistry as indicated (original magnification Â 10 for haematoxylin and eosin and Â 40 for pSmad2). (C) pSmad2 levels were assessed by immunohistochemistry (C) and quantified (D).
Indeed, we found that TGF-b 1 and -b 2 messenger RNA levels declined after integrin inhibition with blocking antibodies or RNA interference or exposure of glioma cells to cilengitide (Fig. 5) . Additionally, TGF-b gene promoters show reduced activity on integrin inhibition with all three approaches. For both TGF-b 1 and TGF-b 2 , similar results were obtained independently from the length of the promoter construct (between 1729-453 bp), indicating that any functionally relevant part of the promoter is even closer to the gene's coding sequence. We also considered the possibility that the cilengitide effects on TGF-b transcription were a result of decreased levels of TGF-b. This interpretation would require that TGF-b controls its own transcription in the experimental system used here. However, previous experiments had not indicated a major contribution of autocrine TGF-b loops to the total TGF-b activity in glioma cell line studies (Leitlein et al., 2001; Uhl et al., 2004) .
The possible clinical importance of our findings was supported by the observation that Smad2 phosphorylation was attenuated in some LN-308 glioma-bearing nude mice treated with cilengitide, identifying the compound as a weak integrin antagonist when pSmad2 phosphorylation is defined as the biological endpoint. The heterogeneous findings here may reflect the clinical situation where cilengitide monotherapy probably neither provides a survival benefit in glioma patients nor causes significant toxicity. A minority of recurrent glioblastoma patients showed durable responses even to cilengitide alone (Reardon et al., 2008) , but a biomarker to identify such patients has not been established. Absence of target integrin expression would be expected to predict failure of clinical benefit from integrin inhibitors and may in the future be assessed non-invasively by Positron emission tomography (PET) (Schnell et al., 2009) . In our animal model, there was little response to cilengitide at the level of pSmad2 levels although the target integrins were expressed (Fig. 6) , indicating that there are either intracellular mechanisms of resistance operating in vivo or that the intrinsic activity of cilengitide is too low, at the dosing schedule used here, or both. However, our findings highlight integrin inhibition as a promising therapeutic approach in glioblastoma and demonstrate that the best way to interfere with integrin signalling still needs to be defined. In summary, the results of this study reveal suppression of the TGF-b pathway as a novel mechanism by which integrin inhibition may be exploited in human patients with TGF-b-dependent tumours such as glioblastoma.
